Abreva



Indications and Reactions:

Role Indications Reactions
Primary
Oral Herpes 85.3%
Product Used For Unknown Indication 8.8%
Drug Use For Unknown Indication 4.0%
Aphthous Stomatitis 0.5%
Chapped Lips 0.3%
Dermatitis 0.1%
Feeling Cold 0.1%
Pyrexia 0.1%
Acne 0.1%
Blister 0.0%
Bronchitis 0.0%
Dry Skin 0.0%
Fungal Infection 0.0%
Genital Herpes 0.0%
Herpes Simplex 0.0%
Herpes Zoster 0.0%
Liver Disorder 0.0%
Molluscum Contagiosum 0.0%
Prophylaxis 0.0%
Sensitivity Of Teeth 0.0%
Drug Ineffective 55.5%
Oral Herpes 17.4%
Herpes Simplex 6.0%
Product Quality Issue 4.4%
Drug Administration Error 4.2%
Swelling Face 2.9%
Intentional Drug Misuse 2.4%
Lip Swelling 1.6%
Application Site Irritation 0.8%
Scar 0.7%
Hypersensitivity 0.6%
Rash 0.5%
Pharmaceutical Product Complaint 0.5%
Application Site Pain 0.5%
Scab 0.4%
Application Site Swelling 0.4%
Lip Dry 0.3%
Lip Pain 0.3%
Lip Haemorrhage 0.3%
Pruritus 0.3%
Secondary
Oral Herpes 50.0%
Herpes Virus Infection 20.0%
Product Used For Unknown Indication 15.0%
Crohn's Disease 5.0%
Herpes Simplex 5.0%
Rheumatoid Arthritis 5.0%
Oral Herpes 20.0%
Product Quality Issue 20.0%
Drug Ineffective 13.3%
Burning Sensation 6.7%
Drug Administration Error 6.7%
Lip Haemorrhage 6.7%
Mouth Ulceration 6.7%
Skin Exfoliation 6.7%
Stomatitis 6.7%
Wound Haemorrhage 6.7%
Concomitant
Anxiety 18.2%
Rheumatoid Arthritis 14.0%
Drug Use For Unknown Indication 9.1%
Oral Herpes 7.4%
Product Used For Unknown Indication 7.4%
Constipation 4.1%
Diabetes Mellitus 4.1%
Hypothyroidism 4.1%
Pregnancy 4.1%
Prophylaxis 4.1%
Hormone Replacement Therapy 3.3%
Pain 3.3%
Asthma 2.5%
Psoriasis 2.5%
Rash 2.5%
Viral Upper Respiratory Tract Infection 2.5%
Abscess 1.7%
Arthritis 1.7%
Blood Pressure 1.7%
Chronic Lymphocytic Leukaemia 1.7%
Drug Ineffective 13.3%
Ventricular Septal Defect 13.3%
Chronic Obstructive Pulmonary Disease 6.7%
Oral Herpes 6.7%
Tendon Disorder 6.7%
Vision Blurred 6.7%
Bacterial Sepsis 3.3%
Bleeding Time Prolonged 3.3%
Constipation 3.3%
Death 3.3%
Deep Vein Thrombosis 3.3%
Dizziness 3.3%
Dysgeusia 3.3%
Endometrial Cancer Metastatic 3.3%
Headache 3.3%
Hypertension 3.3%
Injection Site Pain 3.3%
Injection Site Pruritus 3.3%
Pain 3.3%
Palpitations 3.3%